Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Deaths from obesity-related cancers in the U.S. surged 104% between 1990 and 2023, rising from ~23,000 to over 47,000 annually. Liver, pancreatic, and uterine cancers saw the sharpest spikes, and the age-standardized death rate also climbed — meaning population growth alone doesn't explain the trend. Experts say obesity prevention must be treated as cancer prevention.
Obesity-related cancer deaths in the U.S. more than doubled over the past three decades, jumping 104% from 23,236 in 1990 to 47,450 in 2023, according to data from the Global Burden of Disease 2023 study presented at ObesityWeek. Crucially, the age-standardized death rate also rose — by 8.1% — signaling that the surge goes beyond simple population growth and aging.
Liver, pancreatic, and uterine cancers led the charge, with deaths rising 566%, 487%, and 193%, respectively. Colorectal cancer still accounts for the most total obesity-linked cancer deaths (11,161 in 2023), but the rankings have shifted dramatically. The burden also skews geographic: Southern states like West Virginia, Kentucky, and Mississippi had the highest death rates, while younger women (ages 15–39) saw a 220% rise in uterine cancer disability burden — a warning sign that this isn't just an older adult problem.
By the Numbers:
Why it matters: These findings make a compelling case for treating obesity prevention and treatment as a core pillar of cancer prevention — and for tailoring regional strategies rather than applying a one-size-fits-all approach. Researchers also flagged GLP-1 medications as a variable worth modeling in future projections.